The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology).
R. Soffietti
No relevant relationships to disclose
E. Trevisan
No relevant relationships to disclose
R. Ruda
No relevant relationships to disclose
L. Bertero
No relevant relationships to disclose
C. Bosa
No relevant relationships to disclose
M. G. Fabrini
No relevant relationships to disclose
I. Lolli
No relevant relationships to disclose